Armistice Capital’s AIM ImmunoTech AIM Stock Holding History

Armistice Capital’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-43,343	Closed	-$1.17M	–	321
2024 Q3	$1.17M	Buy	43,343 +2,522	+6%	+$84.1K	0.02%	169
2024 Q2	$1.52M	Buy	+40,821	New	+$1.73M	0.02%	154

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Armistice Capital's AIM Position: Q4 2024 in Review

Armistice Capital sold out of AIM ImmunoTech (AIM) in Q4 2024, closing a stake of 43,343 shares — an estimated $1.17M sold.

Armistice Capital first reported a position in AIM in Q2 2024 and held it in 2 quarters. The position peaked at $1.52M in Q2 2024. 32 funds tracked by Wall St. Rank hold AIM as of Q4 2024.

Armistice Capital reported no remaining AIM ImmunoTech position as of Q4 2024 after selling out during the quarter.
Armistice Capital sold 43,343 AIM ImmunoTech shares in Q4 2024, an estimated $1.17M.
Armistice Capital first reported a position in AIM ImmunoTech in Q2 2024 and held it in 2 quarters.
Armistice Capital's AIM ImmunoTech position peaked at $1.52M in Q2 2024.
32 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2024.

Based on Armistice Capital's 13F filing for Q4 2024, filed 14 Feb 2025.